** Shares of ophthalmic medical device company Rxsight RXST.O fall 23.8% to $19.9 premarket
** Co late on Wednesday lowered its annual revenue forecast to range between $160.0 million and $175.0 million from a previous range of $185 million to $197 million
** RXST expects preliminary Q1 revenue of $37.9 million, lower than analysts' average estimate of $39.59 million as per data compiled by LSEG
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and their median PT is $43 - LSEG data
** Up to last close, RXST stock has fallen 93% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.